RABEEDON-D Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
RABEEDON-D
Rabeprazole 20mg + Domperidone 10mg
RABEEDON-D is an advanced gastro-protective formulation developed for the rapid healing of mucosal erosion, acid peptic disorders, and gastroesophageal reflux disease (GERD).
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
Forms a polyanionic protective barrier coating over inflamed gastric ulcers, preventing enzymatic acid degradation while facilitating tissue re-epithelialization.
Administer on an empty stomach 1 hour before principal meals, or as posology prescribed by the gastroenterologist.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store below 25°C in a dry place. Protect from moisture and direct sunlight.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
RABEEDON-D features Rabeprazole 20mg + Domperidone 10mg prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
Recommended in routine specialist o for RABEEDON-D
RABEEDON-D has been recommended in routine specialist outpatient consultations, ensuring optimal patient compliance thanks to smooth physiological tolerability. Supplied in tamper-evident cartons that withstand high humidity without foil de-lamination. Patient feedback has been overwhelmingly positive with negligible return or complaint rates.
Questions Regarding RABEEDON-D
What is the therapeutic indication and composition of RABEEDON-D?
RABEEDON-D contains Rabeprazole 20mg + Domperidone 10mg indicated for Peptic Ulcer Disease as formulated by Sygnus Biotech.
What packaging presentations are available for RABEEDON-D?
RABEEDON-D is supplied in tamper-evident 10 x 10 Alu-Alu / Blister Pack, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for RABEEDON-D?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for RABEEDON-D along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
RABEEDON-D is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.
Related Formulations in Tablet
View all Tablet →
DAIBET-G2 V
Glimepiride 2mg + Metformin Hydrochloride 500mg + Voglibose 0.2mg Bilayered
